![]() 13% for chemotherapy alone, representing a 34% reduction in the risk of death (HR 0.66 95% CI: 0.50 to 0.86). PD-L1 <1%: Among patients with tumor PD-L1 expression <1%, the OS rate was 23% for those treated with the dual immunotherapy-based combination vs. ![]() With extended follow-up, the clinically meaningful efficacy benefit of Opdivo plus Yervoy with two cycles of chemotherapy was maintained across secondary endpoints and key subgroups of patients, with benefits more pronounced amongst high unmet need patients with tumor PD-L1 expression <1% and squamous histology: ![]() With a minimum follow-up of 47.9 months, the dual immunotherapy-based combination continued to enhance overall survival (OS), the trial’s primary endpoint, with 21% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive compared to 16% of patients treated with chemotherapy alone at four years (Hazard Ratio 0.74 95% Confidence Interval : 0.63 to 0.87). PRINCETON, N.J., June 04, 2023-( BUSINESS WIRE)- Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with metastatic non-small cell lung cancer (NSCLC). Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |